Cannabinoid receptor modulators

Abstract

Provided are certain methods useful in the treatment of pain comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB 2 receptor;

1 - 66 . (canceled) 
     
     
         67 . A pharmaceutical product selected from: a pharmaceutical composition, a formulation, a dosage form, a combined preparation, a twin pack, and a kit; comprising a compound which is: 
       
         
           
           
               
               
           
         
       
       and one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents; and a pharmaceutically acceptable carrier. 
     
     
         68 . The composition of  claim 67 , wherein the compound is an anhydrous crystalline form of: 
       
         
           
           
               
               
           
         
       
     
     
         69 . A method for preparing a composition comprising the step of admixing a compound which is: 
       
         
           
           
               
               
           
         
       
       one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents; and a pharmaceutically acceptable carrier. 
     
     
         70 . The composition of  claim 69 , wherein the compound is an anhydrous crystalline form of: 
       
         
           
           
               
               
           
         
       
     
     
         71 . A method for the treatment of pain in an individual in need thereof, comprising administering to said individual, a composition comprising a compound which is: 
       
         
           
           
               
               
           
         
       
       one or more known pharmaceutical agents selected from: analgesic agents, antidiabetic agents, osteoarthritis agents, and anticancer agents; and a pharmaceutically acceptable carrier;
 wherein the pain is chosen from: bone and joint pain, pain associated with osteoarthritis, hyperalgesia, allodynia, inflammatory pain, inflammatory hyperalgesia, neuropathic pain, neuropathic hyperalgesia, acute nociception, muscle pain, dental pain, migraine and other headache pain, pain that occurs as an adverse effect of therapeutics in an individual, and pain associated with a disorder selected from: cancer, multiple sclerosis, allergic reactions, nephritic syndrome, scleroderma, thyroiditis, diabetic neuropathy, fibromyalgia, HIV related-neuropathy, sciatica, and an autoimmune condition. 
 
     
     
         72 . The method according to  claim 71 , wherein the analgesic agent is chosen from non-opioid drugs, opioid drugs, and co-analgesic medications. 
     
     
         73 . The method according to  claim 72 , wherein the non-opioid drug is chosen from non steroidal anti-inflammatory agents, choline magnesium trisalicylate, sulfasalazine, olsalazin, phenacetin, tenoxicam, phenylbutazone, oxyphenthartazone, tapentadol, celecoxib, etoricoxib, lumiracoxib, rofecoxib, parecoxib, and ziconotide. 
     
     
         74 . The method according to  claim 73 , wherein the non steroidal anti-inflammatory agent is chosen from acemetacin, acetaminophen, aminoprofen, aspirin, benoxaprofen, bucloxic acid, carprofen, choline magnesium salicylate, choline salicylate, clidanac, diclofenac, diflunisal, diflurisal, etodolac, fenoprofen, fenoprofen calcium, fentiazac, flosulide, flubufen, flufenamic acid, flufenisal, flurbiprofen, fluprofen, ibuprofen, indoprofen, indomethacin, isoxicam, ketoprofen, ketorolac tromethamine, lornoxicam, magnesium salicylate, meclofenamic acid, meclofenamate sodium, mefenamic acid, meloxicam, muroprofen, nabumetone, naproxen, nepafenac, niflumic acid, nimesulide, oxaprozin, oxpinac, piroprofen, piroxicam, pramoprofen, ramifenazone, salsalate, salicylsalicylic acid, sodium salicylate, sudoxicam, sulindac, suprofen, tiaprofenic acid, tiopinac, tolfenamic acid, tolmetin, trioxaprofen, zidometacin, and zomepirac. 
     
     
         75 . The method according to  claim 72 , wherein the opioid drug is chosen from: alfentanil, allylprodine, alphaprodine, anileridine, apomorphine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dextropropoxyphene, dezocine, diampromide, diamorphone, dihydrocodeine, dihydrocodeinone enol acetate, dihydromorphine, dilaudid, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodeine, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacylmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, 6-monoacetylmorphine, morphine, morphine-6-glucuronide, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, noscapine, opium, oxycodone, oxymorphone, papavereturn, papverine, pentazocine, pethidine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, and tramadol. 
     
     
         76 . The method according to  claim 71 , wherein the analgesic agent comprises an NSAID and an opioid drug. 
     
     
         77 . The method according to  claim 71 , wherein the analgesic agent is chosen from vicodin, percocet, norco, lorcet, darvocet, and percodan. 
     
     
         78 . The method according to  claim 71 , wherein the analgesic agent is a coanalgesic medication chosen from antidepressants, anti-anxiety medications, migraine medications, and gabapentin. 
     
     
         79 . The method according to  claim 71 , wherein the anticancer agent is chosen from eribulin mesylate, cabazitaxel, sipuleucel-T, degarelix, raloxifene, topotecan hydrochloride, ixabepilone, lapatinib, erlotinib, gefitinib, abarelix, leuprolide acetate, fulvestrant, letrozole, triptorelin pamoate, herceptin, nolvadex, photofrin, xeloda, letrozole, anastrozole, flutamide, gemcitabine HCl, docetaxel, goserelin acetate, bevacizumab, celecoxib, cetuximab, denosumab, ibandronic acid, thyrotropin alfa, trabectedin, and pemetrexed. 
     
     
         80 . The method according to  claim 71 , wherein the osteoarthritis agent is chosen from valdecoxib, meloxicam, etodolac, naproxen sodium, diacerhein, tetracycline, antimalarial therapies, Gen-S, JNJ-39439335, JNJ-42160443, JNS013, N-[5-tert-butyl-2,3-dihydro-1H-inden-1(R)-yl]-N′-(1H-indazol-4-yl)urea, SAR114137, MEDI-578, LY545694, 6,14-ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-(αS,5α,7α)-hydrochloride, GRC 15300, benzamide, 3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethyl-, ADX71943, ELI-216, 1H-pyrrolo[1,2-a]imidazole-2,5(3H,6H)-dione, dihydro-, diractin, XEN 402, CRB 0022, apitoxin, and etoricoxib. 
     
     
         81 . The method according to  claim 71 , wherein the compound is an anhydrous crystalline form of: